These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 27692151)

  • 1. Computed tomography (CT)-assessed bronchodilation induced by inhaled indacaterol and glycopyrronium/indacaterol in COPD.
    Shimizu K; Seto R; Makita H; Suzuki M; Konno S; Ito YM; Kanda R; Ogawa E; Nakano Y; Nishimura M
    Respir Med; 2016 Oct; 119():70-77. PubMed ID: 27692151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.
    Hohlfeld JM; Vogel-Claussen J; Biller H; Berliner D; Berschneider K; Tillmann HC; Hiltl S; Bauersachs J; Welte T
    Lancet Respir Med; 2018 May; 6(5):368-378. PubMed ID: 29477448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regional bronchodilator response assessed by computed tomography in chronic obstructive pulmonary disease.
    Shimizu K; Makita H; Hasegawa M; Kimura H; Fuke S; Nagai K; Yoshida T; Suzuki M; Konno S; Ito YM; Nishimura M
    Eur J Radiol; 2015 Jun; 84(6):1196-201. PubMed ID: 25805332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review.
    Ulrik CS
    Int J Chron Obstruct Pulmon Dis; 2014; 9():331-8. PubMed ID: 24729699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translational Study Searching for Synergy between Glycopyrronium and Indacaterol.
    Cazzola M; Calzetta L; Segreti A; Facciolo F; Rogliani P; Matera MG
    COPD; 2015 Apr; 12(2):175-81. PubMed ID: 25222881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.
    Horita N; Kaneko T
    Int J Chron Obstruct Pulmon Dis; 2015; 10():813-22. PubMed ID: 25960646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD.
    Prakash A; Babu KS; Morjaria JB
    Int J Chron Obstruct Pulmon Dis; 2015; 10():111-23. PubMed ID: 25609944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The combination of indacaterol and glycopyrronium has effects on symptoms, lung function, and rate of exacerbations in COPD patients].
    Ulrik CS
    Ugeskr Laeger; 2014 Sep; 176(38):. PubMed ID: 25294211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
    Ridolo E; Montagni M; Riario-Sforza GG; Baroni M; Incorvaia C
    Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of (a Combination of) the Beta
    Maarsingh H; Oldenburger A; Han B; Zuidhof AB; Elzinga CRS; Timens W; Meurs H; Sopi RB; Schmidt M
    Cells; 2021 May; 10(5):. PubMed ID: 34069899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells.
    Cazzola M; Calzetta L; Puxeddu E; Ora J; Facciolo F; Rogliani P; Matera MG
    Respir Res; 2016 Jun; 17(1):70. PubMed ID: 27296533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium.
    Ficker JH; Rabe KF; Welte T
    Pulm Pharmacol Ther; 2017 Aug; 45():19-33. PubMed ID: 28389258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Indacaterol/Glycopyrronium (IND/GLY) Versus Salmeterol/Fluticasone in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: The Chinese Cohort from the LANTERN Study.
    Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Patalano F; Banerji D
    COPD; 2016 Dec; 13(6):686-692. PubMed ID: 27715335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
    Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life.
    Rossi A; Zanardi E; Poletti V; Cazzola M
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1383-92. PubMed ID: 26229457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relieving exertional dyspnea during the 3-min constant speed shuttle test in patients with COPD with indacaterol/glycopyrronium
    Beaulieu J; Jensen D; O'Donnell DE; Brouillard C; Tracey L; Vincent S; Nadreau É; Bernard E; Bernard S; Maltais F
    Ther Adv Respir Dis; 2020; 14():1753466620939507. PubMed ID: 32663102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair(®) in chronic obstructive pulmonary disease.
    Hoshino M; Ohtawa J; Akitsu K
    Pulm Pharmacol Ther; 2015 Feb; 30():128-33. PubMed ID: 25183687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial.
    Singh D; Wild JM; Saralaya D; Lawson R; Marshall H; Goldin J; Brown MS; Kostikas K; Belmore K; Fogel R; Patalano F; Drollmann A; Machineni S; Jones I; Yates D; Tillmann HC
    Respir Res; 2022 Feb; 23(1):26. PubMed ID: 35144620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
    Mahler DA; Gifford AH; Satti A; Jessop N; Eckert JH; D'Andrea P; Mota F; Banerjee R
    Respir Med; 2016 Jun; 115():39-45. PubMed ID: 27215502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD-a randomised controlled study.
    Salomon J; Stolz D; Domenighetti G; Frey JG; Turk AJ; Azzola A; Sigrist T; Fitting JW; Schmidt U; Geiser T; Wild C; Kostikas K; Clemens A; Brutsche M
    Respir Res; 2017 Jan; 18(1):13. PubMed ID: 28077140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.